Gilead Mobilizes Rapid Donation of Remdesivir to Support Ebola Response, Building on Decade-Long Commitment to Outbreak Relief
Gilead Sciences announced a donation of more than 2,000 vials of remdesivir to Uganda to support the response to the current Ebola Bundibugyo virus disease outbreak. The donation is provided under compassionate use and MEURI frameworks, as remdesivir is not approved for filovirus treatment in any country.
Key figures
- Donation vials
- 2000
- Patients treated mlcc
- 8.1 million
- Planned us investment
- $32 billion
- Total patients treated covid
- 14.5 million
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.